IDEAYA Biosciences reports a $1.22 per share loss for Q2, missing expectations, while revenue rises 35.1% year-over-year to $8.86M.
IDEAYA Biosciences posted a Q2 GAAP loss of $1.22 per share, missing estimates by $0.14. The wider-than-expected loss contrasts with revenue growth of 35.1% year-over-year to $8.86 million, which exceeded forecasts by $1.41 million.
The company reported $1.24 billion in cash, cash equivalents, and marketable securities as of June 30, 2026. Cash runway guidance remains unchanged, extending into 2030.
Shares may face pressure as investors weigh the earnings miss against revenue growth and strong liquidity.